Avenue Therapeutics, Inc. (ATXI)
Largest Insider Buys in Sector
ATXI Stock Price History Chart
ATXI Stock Performance
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Insider Activity of Avenue Therapeutics, Inc.
Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $1,250 and sold $86,560 worth of Avenue Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $178,900 and sold $786,155 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KRANZLER JAY D (director) — $1,250.
The last purchase of 497 shares for transaction amount of $1,243 was made by KRANZLER JAY D (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Avenue Therapeutics, Inc.
| 2024-09-30 | director | 497 0.037% | $2.50 | $1,243 | -15.66% | |||
| 2024-09-27 | director | 3 0.0002% | $2.40 | $7 | -15.94% | |||
| 2023-12-11 | Sale | 10 percent owner | 617,000 4.9094% | $0.14 | $86,560 | -55.39% | ||
| 2023-09-08 | 10 percent owner | 418,410 4.9086% | $0.72 | $301,255 | -80.21% | |||
| 2023-09-08 | director | 348,675 4.0905% | $0.72 | $251,046 | -80.21% | |||
| 2022-10-11 | Sale | director | 388,888 48.3396% | $7.71 | $3M | -59.86% | ||
| 2021-09-15 | Sale | Chief Financial Officer | 7,160 0.042% | $1.62 | $11,599 | -69.16% | ||
| 2021-05-06 | director | 2,500 0.0142% | $3.99 | $9,975 | -68.56% | |||
| 2020-08-20 | Sale | Chief Financial Officer | 3,840 0.0235% | $12.13 | $46,579 | -60.88% | ||
| 2020-03-10 | Chief Financial Officer | 1,889 0.0115% | $7.94 | $14,999 | +12.63% | |||
| 2020-03-09 | Chief Financial Officer | 1,500 0.0093% | $7.99 | $11,983 | +13.49% | |||
| 2020-02-27 | director | 2,400 0.0139% | $8.20 | $19,680 | +3.72% | |||
| 2020-02-26 | director | 161 0.001% | $8.73 | $1,406 | +0.45% | |||
| 2020-02-25 | director | 10,000 0.0629% | $9.31 | $93,100 | -0.89% | |||
| 2020-02-25 | Chief Financial Officer | 1,200 0.0074% | $9.09 | $10,908 | -0.89% | |||
| 2019-09-12 | director | 16,000 0.0982% | $6.27 | $100,320 | +46.39% | |||
| 2019-08-09 | Sale | Chief Financial Officer | 2,375 0.0138% | $5.56 | $13,205 | +49.32% | ||
| 2019-08-08 | Sale | Chief Financial Officer | 2,313 0.0141% | $5.62 | $12,999 | +55.35% | ||
| 2019-06-18 | director | 2,000 0.0126% | $5.83 | $11,660 | +21.09% | |||
| 2019-06-17 | director | 3,000 0.0182% | $5.88 | $17,640 | +15.92% |